Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Sushree Mohanty

BIZARRE: 1 growth stock under 100 to buy before it soars - What They Never Told You

Incyte (INCY) reported a breakout quarter on Oct. 28, beating Wall Street’s revenue and earnings estimates. Best known for its blockbuster drug Jakafi and expanding oncology pipeline, this biotech combines profitability, pipeline depth, and long-term growth potential while trading under $100.

Valued at $18.2 billion, Incyte stock is up 31.9% year-to-date, outperforming the broader market gain of 17.3%. Should you grab this biotech stock now?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.